Hematology/Oncology

Top Story

VIDEO: Anti-CD47 fusion protein well tolerated by patients with solid tumors, non-Hodgkin lymphoma

June 24, 2018
Meeting NewsVideo

VIDEO: Targeted agents may fill unmet needs in non-small cell lung cancer

June 23, 2018
CHICAGO — Robert C. Doebele, MD, PhD, associate professor in the division of medical oncology at University of Colorado Anschutz Medical Campus, spoke with…
Feature

Studies of immunotherapy for prostate cancer yield encouraging results

June 22, 2018
Several studies designed to investigate immunotherapies and immunotherapeutic combinations for treatment of prostate cancer have yielded encouraging results. …

Ruxolitinib shows promising response rate for graft-versus-host disease

June 22, 2018
A phase 2 trial of ruxolitinib met its primary endpoint of overall response rate for the treatment of patients with steroid-refractory graft-versus-host disease…

NBTXR3 with radiotherapy doubles responses for soft tissue sarcoma

June 22, 2018
A trial assessing NBTXR3 plus radiotherapy met its primary endpoint of improved pathologic complete response rate compared with standard of care among patients with soft…
More Headlines »
CME

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

This activity is supported by an educational grant from Merck & Co., Inc.

The integration of immune checkpoint inhibitors into treatment algorithms for patients with bladder cancer who have…
More »
Video
Meeting News

VIDEO: Cemiplimab demonstrates ‘impressive activity’ for metastatic cutaneous squamous cell carcinoma

June 19, 2018
More »
Resource Centers
ASCO Annual Meeting

ASCO Annual Meeting

CME CNE CPE

Exploring New Immune Checkpoint Inhibitor Paradigms in Advanced Melanoma

This activity is supported by an educational grant from Bristol-Myers Squibb.

The integration of immune checkpoint inhibitors into treatment algorithms for the management of advanced genitourinary…
More »
Current Issues
View the Current Issue
HemOnc Today